First Choice Hospice Medicare Approved Location: 966 North Claxton Avenue, Elba, Alabama 36323 Phone: (334) 897-0650 |
News Archive
The two-page form, designed to accommodate religious beliefs, is regarded as an untenable compromise by some religious employers, reports The New York Times. Meanwhile, GOP governors see little fallout from the Supreme Court's contraceptive coverage decision and a poll shows growing Republican support for the court.
Repligen Corporation announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office for a patent covering a recombinant form of Protein A which is identical in structure to the commercial form of Protein A from Staphylococcus aureus which is used in the production of many of the world's approved monoclonal antibodies. The patent, which will remain in force until 2028, covers a new Repligen proprietary product which is now available in commercial quantities.
Scientists from the Tumor Immunotherapy and Microenvironment research group led by Dr Bassam Janji at the Luxembourg Institute of Health Department of Oncology, and the Swedish pharma company Sprint Bioscience published the results of an innovative approach that turns "cold" tumors "hot". "Cold", immune-desert tumors are classically immunotherapy-resistant.
A drug is being studied for its effectiveness in treating a type of severe immune overreaction seen in patients with COVID-19-induced pneumonia by researchers at The University of Texas Health Science Center at Houston.
› Verified 4 days ago